Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
NJBIZ8d
Sun Pharma expanding Princeton HQ with $5.2M in tax credits
The New Jersey Economic Development Authority board March 12 approved $5.24 million in tax credits under the Emerge Program ...
New Jersey Business Magazine7d
Emerge Program Secures Sun Pharma’s Presence in NJ
The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a ...
Sun Pharma to buy US-based oncology firm with new skin cancer treatment product for $355 million
This is also Sun Pharma's second acquisition in less than three months and comes as the company looks to size up its specialty therapy portfolio.
How Trump's Tariffs On India Will Backfire On The US Healthcare System
The US relies heavily on Indian generic medicines, with nearly half of all generic drugs consumed in the US originating from ...
Business Today19h
Sun Pharma Advanced Research Company Ltd (SPARC) Share Price
Sun Pharma Advanced Research Company Ltd share price was up by 2.27% from the previous closing price of ₹144.49. Who are peers of Sun Pharma Advanced Research Company Ltd? The peers of Sun ...
US tariffs on India will be a bitter pill to swallow
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...